Insights Into Breast Cancer

Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease

Southwest – January 14, 2023

Faculty Chair

Joyce O'Shaughnessy, MD

Texas Oncology, Dallas, TX, USA

Southeast – March 11, 2023

Faculty Chair

Reshma Mahtani, DO

University of Miami Health System, Miami, FL, USA

Central – April 22, 2023

Faculty Chair

Virginia Kaklamani, MD

UT Health San Antonio, San Antonio, TX, USA

St Louis Summit – August 5, 2023

Faculty Chair

Nusayba Ali Bagegni, MD

Washington University, St. Louis, MO, USA

Midwest – August 26, 2023

Faculty Chair

Vijayakrishna Gadi, MD, PhD

University of Illinois, Champaign, IL

California – September 8, 2023

Faculty Chair

Melinda Telli, MD

Stanford University School of Medicine, Stanford, CA, USA

Northeast – September 9, 2023

Faculty Chair

Ian Krop, MD

Dana-Farber Cancer, Boston, MA, USA

Massachusetts – September 23, 2023

Faculty Chair

Sara Tolaney, MD

Dana-Farber Cancer, Boston, MA, USA

Tennessee – October 7, 2023

Faculty Chair

Sonya Reid, MD, MPH

Vanderbilt University Medical Center, Nashville, TN, USA

Florida – October 14, 2023

Faculty Chair

Reshma Mahtani, DO

Miami Cancer Institute, Miami Beach, FL, USA

Northwest – November 2023

Faculty Chair

TBC

TBC

More Information

  • Las Vegas, NV
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Atlanta, GA
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Dallas, TX
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Chicago, IL
  • Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • New York, NY
  • Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Seattle, WA
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of breast cancer
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained
    • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
    • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
    • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.